Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
NCT04561986Phase 3Active, not recruiting
- Sponsor
- Region Västra Götaland
- Start
- Feb 2022
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 3 trial of tocilizumab in antibody mediated rejection (AMR), sponsored by Region Västra Götaland. Started Feb 2022; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT04561986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561986.